Incannex Healthcare: On February 28, 2024, Incannex Healthcare Inc. Announced That They Obtained Positive Topline Results From Its Phase 2 Psigad1 Clinical Trial Of Psilocybin In Generalised Anxiety Disorder. Further Information Is Included In The Press Release Attached As Exhibit 99.1 Hereto, Which Is Incorporated By Reference Into This Item 8.01, Financial Statements And Exhibits
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameIncannex Healthcare Limited (formerly Impression Healthcare Limited)
-
Registration countryUSA
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









